OBJECTIVES Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. MATERIALS AND METHODS The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. RESULTS A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). CONCLUSION BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.

中文翻译：

---

体重指数对非小细胞肺癌患者抗PD-1 / PD-L1抗体功效的影响。

目的据报道，体重指数（BMI）与免疫检查点抑制剂（ICI）在实体瘤（例如黑素瘤）中的功效有关。但是，尚不清楚这种关系是否存在于用程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）抑制剂治疗的非小细胞肺癌（NSCLC）中。这项研究的目的是探讨晚期NSCLC患者的BMI与ICI治疗疗效之间的关系。材料与方法回顾性研究了2015年12月至2018年5月在九家机构接受PD-1 / PD-L1抗体单药治疗的NSCLC患者的病历。在两个队列中研究了BMI的影响。队列1包括以Pembrolizumab作为一线治疗的高PD-L1表达（≥50％）的NSCLC患者，队列2包括以nivolumab / pembrolizumab / atezolizumab治疗作为第二线或后线治疗的NSCLC患者。结果分析了九个机构的513例（队列1中84例，队列2中429例）。使用22 kg / m2的BMI临界值（在我国是理想的BMI）（高BMI​​：22.0和低BMI：22.0），高BMI和低BMI患者之间的PFS或OS没有显着差异在队列1中，但是，在BMI高而低的患者中，生存期明显更长（PFS：3.7 vs. 2.8个月，p = 0.036； OS：15.4 vs. 13.5个月，p = 0.021）。